ProCE Banner Activity

PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance Of Testing For Biomarkers Along With Current Treatment Landscape: Podcast Pearls

PDF
Podcast Episodes
In this downloadable PDF summary from a CCO podcast, Philip Philip, MD, PhD and Elena Chiorean, MD discuss the role of biomarker testing and PARP inhibitors in the treatment of pancreatic cancer.

Released: November 03, 2021

Expiration: November 02, 2022

No longer available for credit.

Share

Faculty

Elena Gabriela Chiorean

Elena Gabriela Chiorean, MD

Professor of Medicine
Division of Medical Oncology
Department of Medicine
University of Washington
Member
Fred Hutchinson Cancer Research
Seattle, Washington

Philip Agop Philip

Philip Agop Philip, MD, PhD, FRCP

Professor
School of Medicine
Wayne State University
Leader, Gastrointestinal Multidisciplinary Team
Department of Oncology
Karmanos Cancer Institute
Detroit, Michigan

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Elena Gabriela Chiorean, MD

Professor of Medicine
Division of Medical Oncology
Department of Medicine
University of Washington
Member
Fred Hutchinson Cancer Research
Seattle, Washington

Philip Agop Philip, MD, PhD, FRCP

Professor
School of Medicine
Wayne State University
Leader, Gastrointestinal Multidisciplinary Team
Department of Oncology
Karmanos Cancer Institute
Detroit, Michigan